Physician profile
Daniel Young
NPI 1265656425
$65,446.62
in general payments reported to CMS, 2019-2025
20 companies · $25K in 2025
The $25K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $878 · 2021: $1,276 · 2022: $1,867 · 2023: $15K · 2024: $20K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Travel and Lodging: $6,895 · Food and Beverage: $6,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,870.00 |
| Travel and Lodging | $6,894.95 |
| Food and Beverage | $6,289.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $57,940.11 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,714.83 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Insmed, INC. | $1,353.84 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $1,114.08 | 2019-2025 | Avycaz, Teflaro, Dalvance |
| Merck Sharp & Dohme LLC | $887.30 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Cumberland Pharmaceuticals, INC. | $762.03 | 2019-2025 | Vibativ |
| La Jolla Pharmaceutical Company | $341.52 | 2020-2025 | Xerava, Zevtera |
| Allergan, INC. | $326.05 | 2019-2020 | |
| Astellas Pharma US INC | $242.18 | 2019-2024 | Cresemba |
| Paratek Pharmaceuticals, INC. | $183.06 | 2019-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $104.83 | 2020-2025 | Cuvitru, Gattex |
| Shionogi INC | $88.72 | 2022-2025 | Fetroja |
| Janssen Biotech, INC. | $85.57 | 2021-2023 | Symtuza |
| Pfizer INC. | $74.07 | 2020-2025 | |
| Tetraphase Pharmaceuticals, INC. | $65.26 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $59.67 | 2022 | |
| Melinta Therapeutics, LLC | $49.54 | 2025 | Rezzayo |
| Nestle Healthcare Nutrition INC. | $19.92 | 2023 | |
| Nabriva Therapeutics, Plc | $17.33 | 2021 | |
| Kerecis Limited | $16.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.